
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics has projected top-line revenues of approximately $32 million for 2025, which are expected to increase significantly to $130.4 million in 2026, indicating a strong growth trajectory. The company's favorable market access situation could enhance coverage and drive additional revenue, contributing to an optimistic outlook for the future. Furthermore, the potential of its pipeline assets in gene therapies and treatments for rare genetic diseases may provide further incremental upside to financial forecasts.
Bears say
Abeona Therapeutics faces significant risks that could adversely impact its financial outlook, primarily due to the anticipated slower than projected uptake of pz-cel in the United States following its market introduction. Additionally, the company's ability to optimize the value of pz-cel outside the U.S. remains uncertain, raising concerns about revenue potential and market access. Furthermore, setbacks in earlier-stage pipeline programs and the possibility of long-term dilution risk for shareholders contribute to an overall negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares